Pfizer Inc Quick Ratio (PFE) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Pfizer Inc  (NYSE: PFE)

Pfizer Inc's Quick Ratio

PFE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Pfizer Inc's Cash & cash equivalent grew by 20.4 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Pfizer Inc's Quick Ratio to 0.79, Quick Ratio remained below Pfizer Inc average.

Within Major Pharmaceutical Preparations industry 370 other companies have achieved higher Quick Ratio than Pfizer Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 2938, from total ranking in the second quarter 2026 at 2989.

Explain Quick Ratio?
How much Cash & cash equivalents PFE´s has?
What are PFE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PFE/financial-strength
https://api.csimarket.com/api/v1/companies/PFE/fundamentals
https://api.csimarket.com/api/v1/companies/PFE/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PFE Quick Ratio (Sep 27 2026)
Q3		 (Jun 28 2026)
Q2 		(Mar 29 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 28 2025)
Q3
Y / Y Current Liabilities Change -13.31 %
Y / Y Cash & cash equivalent Change 67.78 %
Quick Ratio MRQ 0.79
PFE's Total Ranking # 2938
Seq. Current Liabilities Change -2.82 %
Seq. Cash & cash equivalent Change 20.4 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 371
Healthcare Sector # 672
Overall Market # 2184


Quick Ratio Statistics
High Average Low
2.19 0.88 0.16
(June 30. 2009)   (Jun 30 2024)




Financial Statements
Pfizer Inc's Current Liabilities $ 31,726 Millions Visit PFE's Balance sheet
Pfizer Inc's Cash & cash equivalent $ 25,140 Millions Visit PFE's Balance sheet
Source of PFE's Sales Visit PFE's Sales by Geography


Cumulative Pfizer Inc's Quick Ratio

PFE's Quick Ratio for the trailling 12 Months

PFE Quick Ratio

 (Sep 27 2026)
12 Months		 (Jun 28 2026)
12 Months 		(Mar 29 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 28 2025)
12 Months
Y / Y Current Liabilities TTM Growth -11.75 %
Y / Y Cash & cash equivalent TTM Growth 6.36 %
Quick Ratio TTM 0.61
Total Ranking TTM # 3687
Seq. Current Liabilities TTM Growth -3.46 %
Seq. Cash & cash equivalent TTM Growth 14.03 %

Quick ratio ranking by company, industry and sector >> Back to PFE Financial Strength Comparisons >> Go to Compare PFE Quick Ratio to its Competitors

On the trailing twelve months basis PFE Cash & cash equivalent soared by 67.78 % in Q3 2026 year on year, while Current Liabilities decreased to $31,726 millions, this led to increase in in Pfizer Inc's Quick Ratio to 0.61, above PFE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 444 other companies have achieved higher Quick Ratio than Pfizer Inc. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 4085.

Explain Quick Ratio?
How much Cash & cash equivalents PFE´s has?
What are PFE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 445
Healthcare Sector # 913
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
0.25 0.09 0.02
(Apr 04 2021)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Sep 27 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 27 2026 MRQ Cash & cash equivalentSep 27 2026 MRQ Current Liabilities
Maravai Lifesciences Holdings Inc   2.14 $ 73.023  Millions$ 34.160  Millions
Ernexa Therapeutics Inc   2.13 $ 5.575  Millions$ 2.614  Millions
Madrigal Pharmaceuticals Inc   2.12 $ 962.387  Millions$ 454.244  Millions
Puma Biotechnology Inc   2.09 $ 108.575  Millions$ 51.971  Millions
Corcept Therapeutics Inc  2.09 $ 370.703  Millions$ 177.675  Millions
Biomea Fusion Inc   2.07 $ 26.403  Millions$ 12.771  Millions
Dianthus Therapeutics Inc   1.95 $ 55.686  Millions$ 28.515  Millions
Xeris Biopharma Holdings Inc   1.95 $ 262.164  Millions$ 134.479  Millions
Ars Pharmaceuticals Inc   1.95 $ 138.354  Millions$ 70.995  Millions
Lite Strategy Inc   1.92 $ 4.281  Millions$ 2.234  Millions
Mineralys Therapeutics Inc   1.91 $ 101.273  Millions$ 53.075  Millions
Amarin Corp Plcuk  1.85 $ 323.379  Millions$ 175.136  Millions
Mustang Bio inc   1.80 $ 14.276  Millions$ 7.947  Millions
Biovie Inc   1.78 $ 7.733  Millions$ 4.350  Millions
Alnylam Pharmaceuticals Inc   1.74 $ 3,587.255  Millions$ 2,063.006  Millions
Mallinckrodt Plc  1.74 $ 1,085.600  Millions$ 624.900  Millions
Insmed Inc  1.73 $ 1,146.626  Millions$ 662.181  Millions
Nkarta Inc   1.72 $ 48.354  Millions$ 28.072  Millions
Mannkind Corporation  1.67 $ 181.525  Millions$ 108.524  Millions
Verastem Inc   1.67 $ 172.801  Millions$ 103.328  Millions
Agios Pharmaceuticals Inc   1.66 $ 128.549  Millions$ 77.588  Millions
Bridgebio Pharma Inc   1.57 $ 1,538.855  Millions$ 977.237  Millions
Arcutis Biotherapeutics Inc   1.51 $ 259.460  Millions$ 172.357  Millions
Regeneron Pharmaceuticals Inc   1.50 $ 9,301.100  Millions$ 6,202.100  Millions
Emergent Biosolutions Inc   1.44 $ 175.700  Millions$ 122.000  Millions
Arbutus Biopharma Corp  1.39 $ 337.490  Millions$ 241.933  Millions
Compass Pathways Plc  1.36 $ 443.979  Millions$ 325.863  Millions
Sarepta Therapeutics Inc   1.34 $ 878.776  Millions$ 656.353  Millions
Zai Lab Limited  1.32 $ 559.658  Millions$ 424.249  Millions
Urogen Pharma Ltd   1.31 $ 96.901  Millions$ 74.031  Millions

Date modified: 2026-11-04T15:23:31+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.